alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Materials Not Included in

Airworthiness Directive (AD) Docket

 Docket Number: FAA-2013-1067

 Directorate Identifier: 2013NM164AD

84-24-53 --- 5/11/12

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the 

Supplemental AD Docket

MAY BE VIEWED AT: Federal Aviation Administration

Transport Airplane Directorate

Rules Docket

1601 Lind Ave. SW.,

Renton, WA 98057

425.227.1221

DURING THE HOURS OF: 9 a.m. and 3 p.m., Monday through Friday,

except Federal holidays.

Form Date: 03/05/2008
Exhibit 32.1



CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, John Hiner, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)  the quarterly report on Form 10-QSB of Geocom Resources Inc. (the Company) for the interim period ended December 31, 2008 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:  March
13, 2008



[ex311001.jpg]



John Hiner

President and Director

(Principal Executive Officer)



A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Geocom Resources Inc. and will be retained by Geocom Resources Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
**Exhibit 10.35**

 

Trimeris, Inc. 

Description of Non-Management Director Compensation Arrangements 

 

Following is a description of the compensation arrangements for each of the Company’s non-management directors. We reimburse our directors for all reasonable and necessary travel and other incidental expenses incurred in connectionwith their attendance at meetings of the Board. In addition, all eligible non-management directors, except the Chairman, automatically receive a grant of an option on the date of our annual meeting to purchase 10,000 shares of common stock. TheChairman automatically receives a grant of an option on the date of our annual meeting to purchase 15,000 shares of common stock. In addition, all eligible non-employee directors serving as members of the Compensation and Governance Committee orAudit and Finance Committee, except the directors serving as chairmen of these committees, receive an option on the date of our annual meeting to purchase 1,250 shares of common stock. The directors serving as chairmen of these committees eachreceive a grant of an option at the date of our annual meeting to purchase 2,500 shares of common stock. These options have an exercise price equal to 100% of the fair market value of our common stock on the grant date and become exercisable afterthe completion of one year of service following the grant. Newly-elected directors are granted an option to purchase 20,000 shares of common stock, with the options vesting ratably over the three years. These options have an exercise price equal to100% of the fair market value of our common stock on the grant date. Members of our Nominating Committee do not receive any compensation for serving on this committee.
Exhibit 32.1




CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002






In connection with the Quarterly Report of GlobeTrac Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John daCosta, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:




(1)   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




/s/John daCosta


Chief Executive Officer


November 15, 2010
| “2.1 | Object - Subject to the terms and conditions of this Agreement, the Licensor hereby transfers unto Licensee the copyright to the WORK, and further grants to Licensee the worldwide and exclusive license to use the WORK and to authorize the use thereof for and in connection with the following purposes:” |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| “Licensor”                                                                                                                                                                         | “Licensee”                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Global Entertainment Holdings, Inc.                                                                                                                                                            | Global Universal Pictures, Inc.                                                                                                                     |
|                                                                                                                                                                                           |                                                                                                                                                |
|                                                                                                                                                                                           |                                                                                                                                                |
| By: /s/ Gary Rasmussen                             | By: Jacqueline Giroux                      |
| Gary Rasmussen                                                                                                                                                                                 | Jacqueline Giroux                                                                                                                                   |
| Its:  CEO                                                                                                                                                                            | Its:  President                                                                                                                           |
#### RIVERTON COUNTRY CLUB, COMPLAINANT-APPELLANT, v. ELSIE W. THOMAS, ET AL., DEFENDANTS-RESPONDENTS.

Argued October 11, 1948

Decided November 1, 1948.

*Mr. W. Louis Bossle,*argued the cause for the complainant-appellant *(Messrs. Tyler & Tyler,*attorneys,).

*Mr. Charles F. Richman*argued the cause for the defendants-respondents.

Per Curiam.

The decree appealed from will be affirmed for the reasons expressed in the opinion filed by Vice Chancellor Woodruff in the court below.

*For affirmance:*Chief Justice Vanderbilt and Justices Case, Heher, Wacheneeld, Burling and Ackerson—6.

*For reversal:*None.
```

[Congressional Bills 104th Congress]
[From the U.S. Government Publishing Office]
[S. 1782 Introduced in Senate (IS)]

104th CONGRESS
  2d Session
                                S. 1782

To amend the Harmonized Tariff Schedule of the United States to provide 
    for duty free treatment for certain injection molding machines.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 20, 1996

   Mr. Craig introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
To amend the Harmonized Tariff Schedule of the United States to provide 
    for duty free treatment for certain injection molding machines.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ELIMINATION OF DUTY ON CERTAIN INJECTION MOLDING MACHINES.

    (a) In General.--Subheading 8477.10.80 of the Harmonized Tariff 
Schedule of the United States is amended to read as follows:
    

          ``     8477.10.80        Other...........  Free               Free (A, CA, E,                         
                                                                         IL, J, MX)        35%                  
                                                                                                              ''

    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER  CALLISTO PHARMACEUTICALS, INC.  FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2007  PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED  PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002

I am the Chief Executive Officer of Callisto Pharmaceuticals, Inc., a Delaware corporation (the "Company"). I am delivering this certificate in connection
with the Form 10-Q of the Company for the quarter ended September 30, 2007 and filed with the Securities and Exchange Commission ("Form 10-Q").

Pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the
Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the
Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

|Date: November 14, 2007 | /s/GARY S. JACOBGary S. Jacob Chief Executive Officer
|----------------------- | -----------------------------------------------------

---



QuickLinks
<PAGE>   1
                                                                      Exhibit 23



                         CONSENT OF INDEPENDENT AUDITORS


We consent to the incorporation by reference in the Registration Statement (Form
S-3 No. 33-64310) of Watson General Corporation and in the related Prospectus of
our report dated December 12, 1996, with respect to the consolidated financial
statements of Watson General Corporation included in this Annual Report (Form
10-K) for the year ended September 30, 1996.



                                                           /s/ Ernst & Young LLP



Orange County, California
December 24, 1996
Exhibit
32.2




CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002






In
connection with the Quarterly Report of In Veritas Medical Diagnostics, Inc.
(the "Company") on Form 10-QSB for the quarter ended January 31, 2008 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, Martin E. Thorp, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:




(1) The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities and Exchange Act of 1934; and




(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and result of operations of the Company.




A signed
original of this written statement required by Section 906 has been provided to
In Veritas Medical Diagnostics, Inc. and will be retained by In Veritas Medical
Diagnostics, Inc. and furnished to the Securities and Exchange Commission or its
staff upon request.





March 14,
2008





/s/
Martin E. Thorp


_______________________________


Martin E.
Thorp


Chief
Financial Officer
#### UNITED STATES of America, Plaintiff-Appellee, v. Michael L. SHORT, Defendant-Appellant.

No. 02-4235.

United States Court of Appeals, Fourth Circuit.

Submitted Nov. 26, 2002.

Decided Jan. 31, 2003.

Christopher B. Parkerson, David Cromwell Johnson & Associates, Birmingham, Alabama, for Appellant. John L. Brown-lee, United States Attorney, Eric M. Hurt, Assistant United States Attorney, Abing-don, Virginia, for Appellee.

Before NIEMEYER, MICHAEL, and MOTZ, Circuit Judges.

Affirmed by unpublished PER CURIAM opinion.

OPINION

PER CURIAM.

Michael L. Short appeals his convictions for conspiracy to distribute and possession with intent to distribute oxycodone, use of a firearm during a drug trafficking offense, and unlawful use of a controlled substance while being in possession of a firearm, all in violation of 18 U.S.C. §§ 922(g)(3), 924(c)(1) (2000); 21 U.S.C. §§ 841(a), 846 (2000).

Short first claims that his receipt of firearms as payment for oxycodone does not amount to “use” of a firearm within the meaning of 18 U.S.C. § 924(c)(1)(A), and that the district court consequently erred in denying his motion for judgment of acquittal. Section 924(c) proscribes this form of bartering. *See Bailey v. United States, 516*U.S. 137, *143, 116*S.Ct. 501, 133 L.Ed.2d 472 (1995); *cf. United States v. Garnett,*243 F.3d 824, 828-29 (4th Cir. 2001) (holding that “trading a firearm for drugs” amounts to “use” of a firearm within the meaning of the Sentencing Guidelines). Accordingly, we conclude that a judgment of acquittal was unwarranted in regard to this issue.

*184Short next claims that the district court erred by admitting hearsay testimony pursuant to Fed.R.Evid. 801(d)(2)(E). Prior to admitting the statement of a co-conspirator, the district court must establish by a preponderance that the statement is made by the defendant’s co-conspirator during the course and in furtherance of a conspiracy. Fed.R.Evid. 801(d)(2)(E); *see also United States v. Hines,*717 F.2d 1481, 1488 (4th Cir.1983). Short asserts that the Government never established a conspiracy. We disagree. The Government need not show an explicit agreement between the parties. Rather, the appropriate analysis is whether the parties acted with the requisite agreement, linked by their mutual interests to sustain the “overall enterprise of catering to the ultimate demands of a particular drug consumption market.” *United States v. Banks,*10 F.3d 1044, 1054 (4th Cir.1993). On the record before us, we conclude the Government established the conspiracy by a preponderance of the evidence as a prerequisite to admission of the challenged evidence. Accordingly, the statements of Short’s co-conspirator were admissible. This claim, likewise, merits no relief.

We affirm the judgment of the district court. We dispense with oral argument, because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*AFFIRMED*
**EXHIBIT
      99.2**





**Certification
      Pursuant to 18 U.S.C. Section 1350 As Adopted Pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002**





I,
      Adam
      Mauerberger, President and Chief Financial Officer of Atlantic Wine Agencies
      Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley
      Act
      of 2002, 18 U.S.C. Section 1350, that:





(1)  the
      Quarterly Report on Form 10-QSB of the Company for the quarter ended June 30,
      2007 (the "Report") fully complies with the requirements of Section 13(a) or
      15(d) of the Securities Exchange Act of 1934, as amended; and





(2)  the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the
      Company.





Date:
      August 14, 2007








/s/
      Adam
      Mauerberger





Adam
      Mauerberger


President
      and Chief Financial Officer
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING

MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL

OF FLORIDA

SECOND DISTRICT

DEVIN ERIC LAMM, )

)

Appellant, )

)

v. ) Case No. 2D19-617

)

STATE OF FLORIDA, )

)

Appellee. )

___________________________________)

Opinion filed October 2, 2019.

Appeal pursuant to Fla. R. App. P.

9.141(b)(2) from the Circuit Court 

for Pasco County; Mary Handsel, 

Judge.

Devin Eric Lamm, pro se.

PER CURIAM.

Affirmed. See Melvin v. State, 645 So. 2d 448 (Fla. 1994); Hughes v. 

State, 22 So. 3d 132 (Fla. 2d DCA 2009); Waiter v. State, 965 So. 2d 861 (Fla. 2d DCA 

2007); Coughlin v. State, 932 So. 2d 1224 (Fla. 2d DCA 2006) (en banc); Shortridge v. 

State, 884 So. 2d 321 (Fla. 2d DCA 2004).

KELLY, MORRIS, and BADALAMENTI, JJ., Concur.
**EXHIBIT 31.2****PC MALL, INC.****CERTIFICATION**I, Brandon H. LaVerne, certify that:1. I have reviewed this Quarterly Report on Form 10-Q of PC Mall, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report; 3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in thisreport; 4. The registrant’s other certifying officers and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controlsand procedures to be designed under our supervision, to ensure that material informationrelating to the registrant, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period in which this report isbeing prepared;  b) Evaluated the effectiveness of the registrant’s disclosure controls and proceduresand presented in this report our conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered by this report based on suchevaluation; and  c) Disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internal controlover financial reporting; and5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performing the equivalentfunctions): a) All significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affectthe registrant’s ability to record, process, summarize and report financial information;and  b) Any fraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financial reporting.   Date:August 13, 2007     /s/ Brandon H. LaVerne Brandon H. LaVerne  Interim Chief Financial Officer
```

[Congressional Bills 104th Congress]
[From the U.S. Government Publishing Office]
[S. 178 Engrossed in Senate (ES)]

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
104th CONGRESS
  1st Session
                                 S. 178

_______________________________________________________________________

                                 AN ACT

 
To amend the Commodity Exchange Act to extend the authorization for the 
     Commodity Futures Trading Commission, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``CFTC Reauthorization Act of 1995''.

SEC. 2. AUTHORIZATION OF APPROPRIATIONS.

    Section 12(d) of the Commodity Exchange Act (7 U.S.C. 16(d)) is 
amended to read as follows:
    ``(d) There are authorized to be appropriated such sums as are 
necessary to carry out this Act for each of fiscal years 1995 through 
2000.''.

            Passed the Senate February 10 (legislative day, January 
      30), 1995.

            Attest:

                                                             Secretary.
104th CONGRESS

  1st Session

                                 S. 178

_______________________________________________________________________

                                 AN ACT

To amend the Commodity Exchange Act to extend the authorization for the 
     Commodity Futures Trading Commission, and for other purposes.
```
Exhibit 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of In Veritas Medical Diagnostics, Inc.
(the "Company") on Form 10-QSB for the quarter ended April 30, 2005 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, John Fuller, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities and Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.

A signed original of this written statement required by Section 906 has been
provided to In Veritas Medical Diagnostics, Inc. and will be retained by In
Veritas Medical Diagnostics, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.



June 20, 2005                              /s/ John Fuller
                                           -------------------------------------
                                           John Fuller
                                           President and Chief Executive Officer